P1413: DOES TOCILIZUMAB INCREASE THE RISK OF INFECTIONS IN PATIENTS UNDERGOING CAR-T THERAPY?

P1413: DOES TOCILIZUMAB INCREASE THE RISK OF INFECTIONS IN PATIENTS UNDERGOING CAR-T THERAPY?

Bibliographic Details
Main Authors:	Sophie Greenhalgh, Mona Asslan, Fiona Dignan, Shahid Iqbal, Jane Norman, Mahmoud Bokhary, Lourdes Calvente Rubio, Elizabeth Davies, Mark Henry, Katie Brice, Lindsey Mannion, Eleni Tholouli
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972540.84358.45

Similar Items

The reduced incidence of respiratory viral infections in transplant recipients during the COVID-19 pandemic – A retrospective observational cross-sectional analysis of admissions to a tertiary haematology unit
by: Hamzah Z. Farooq, et al.
Published: (2023-11-01)

Prameny vyškovských synodálních statut (1413)
by: Pavel Krafl
Published: (1995-06-01)

14.13 Economics and Psychology, Spring 2004
by: Gabaix, Xavier
Published: (2021)

Seminar Al-Quran Antarabangsa 1413H/1993M /
by: Seminar Al-Quran antarabangsa (1993 : Kuala Lumpur), et al.
Published: (1993)

Town, crown, and urban system: the position of towns in the English polity, 1413-71
by: Hartrich, E
Published: (2014)

Dauphin Louis and the University of Paris: An attempt to seize power in France in April – May 1413
by: Nuzhdin, Oleg I.
Published: (2024-03-01)

1413 Immunogenicity of SARS-CoV-2 mRNA vaccines in individuals with thymic epithelial tumors
by: Arun Rajan, et al.
Published: (2023-11-01)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
by: Neven Mohamed Sarhan, et al.
Published: (2023-04-01)

Tocilizumab (Actemra)
by: Martin Sheppard, et al.
Published: (2017-09-01)

Probing the evolution of galaxy clusters using SZ effect and non-thermal emission: First results from A1413
by: Pachchigar M., et al.
Published: (2024-01-01)

Resenha de: Le Domaine du Roi et les finances extraordinaires sous Charles VI (1388-1413)
by: Eurípedes Simões de Paula
Published: (1966-09-01)

The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis
by: Naeem Desai, et al.
Published: (2023-11-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY
by: Shota Yokoyama, et al.
Published: (2023-08-01)

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization
by: Aurélie Truffot, et al.
Published: (2021-12-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01)

Tocilizumab-Induced Erythema Annulare Centrifugum
by: Ana Luísa João, et al.
Published: (2022-10-01)

Efficacy of Tocilizumab in Patients with COVID-19
by: Ahmad Alikhani, et al.
Published: (2022-12-01)

P1413: TRANSCRIPTION FACTOR-DRIVEN COORDINATION OF CELL CYCLE EXIT AND SPECIFICATION OF CELL IDENTITY IN VIVO DURING GRANULOCYTIC DIFFERENTIATION - IN MEMORIAM PROF. NIELS BORREGAARD
by: K. Theilgaard-Mönch, et al.
Published: (2022-06-01)

Tocilizumab-associated multifocal cerebral thrombotic microangiopathy
by: Jewell, P, et al.
Published: (2016)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
by: V. I. Petrov, et al.
Published: (2022-04-01)

Urticarial drug eruption following tocilizumab administration
by: Hikaru Nanamori, et al.
Published: (2022-10-01)

Use of tocilizumab for rheumatoid arthritis: new evidence
by: Evgeny Lvovich Nasonov
Published: (2011-12-01)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021-04-01)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
by: Hua Liao, et al.
Published: (2022-10-01)

Treatment of the Patient with COVID-19 Pneumonia with Tocilizumab
by: Özgür GÜNAL, et al.
Published: (2020-06-01)

Which endometrial preparation protocol provides better pregnancy and perinatal outcomes for endometriosis patients in frozen-thawed embryo transfer cycles? A retrospective study on 1413 patients
by: Yaxin Guo, et al.
Published: (2023-01-01)

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects
by: Hongjie Qian, et al.
Published: (2023-09-01)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
by: Alyaa Elhazmi, et al.
Published: (2023-03-01)

Autoimmune pain due to CASPR2 responsive to tocilizumab
by: Boby V Maramattom
Published: (2024-01-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Preliminary Efficacy of Tocilizumab Treatment in the Patients with COVID-19
by: Yu Chen, et al.
Published: (2021-04-01)

Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
by: Kuo-Tung Tang, et al.
Published: (2023-06-01)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
by: Konstantinos Pagkratis, et al.
Published: (2022-06-01)

Impact of tocilizumab therapy on fatigue in patients with rheumatoid arthritis
by: Anna Sergeyevna Starkova, et al.
Published: (2012-06-01)

Pilot study of tocilizumab monotherapy for active chronic periaortitis
by: Wen Zhang, et al.
Published: (2023-03-01)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol’skaja, et al.
Published: (2015-11-01)

Tocilizumab for refractory morphea in adults: A case series
by: Sarah Lonowski, MD, MBA, et al.
Published: (2022-12-01)